FGF-2 Polyclonal Antibody
¥680.00
- 产品信息
商品描述
靶点-Target
IL-2Rβ
反应性
Human,Mouse,Rat
应用
WB,IF,ELISA
宿主物种-Host Species
Rabbit
同种型-Isotype
IgG
修饰-Modification
Unmodified
MW(Observed)
61kD
推荐稀释比
WB 1:500-1:2000;IF 1:200-1:1000;ELISA 1:10000;Not yet tested in other applications.
组成
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
纯化工艺
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
储存
-15°C to -25°C/1 year(Do not lower than -25°C)
浓度
1 mg/ml
克隆性
Polyclonal
免疫原
The antiserum was produced against synthesized peptide derived from human IL-2R beta. AA range:331-380
特异性
IL-2Rβ Polyclonal Antibody detects endogenous levels of IL-2Rβ protein.
基因名称
IL2RB
蛋白名称
Interleukin-2 receptor subunit beta
别名
IL2RB;Interleukin-2 receptor subunit beta;IL-2 receptor subunit beta;IL-2R subunit beta;IL-2RB;High affinity IL-2 receptor subunit beta;p70-75;p75;CD antigen CD122
Organism-1
Human
基因ID-1
3560
SwissProt-1
P14784
Organism-2
Mouse
基因ID-2
16185
SwissProt-2
P16297
Organism-3
Rat
基因ID-3
25746
SwissProt-3
P26896
背景
The interleukin 2 receptor, which is involved in T cell-mediated immune responses, is present in 3 forms with respect to ability to bind interleukin 2. The low affinity form is a monomer of the alpha subunit and is not involved in signal transduction. The intermediate affinity form consists of an alpha/beta subunit heterodimer, while the high affinity form consists of an alpha/beta/gamma subunit heterotrimer. Both the intermediate and high affinity forms of the receptor are involved in receptor-mediated endocytosis and transduction of mitogenic signals from interleukin 2. The protein encoded by this gene represents the beta subunit and is a type I membrane protein. The use of alternative promoters results in multiple transcript variants encoding the same protein. The protein is primarily expressed in the hematopoietic system. The use by some variants of an alternate promoter in an up
细胞定位
Cell membrane ; Single-pass type I membrane protein .
